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INTRODUCTION
It is perhaps surprising that most of the cells within the bulk of a breast tumor are differentiated cells, which indeed do not have tumorigenic potential at all. The Tumor Initiating Cells (TIC) comprise a small population that can generate tumors with very small amounts (for example, as little as 100 cells) once injected in immunodeficient mice (1) (2) (3) (4) . These cells, named Cancer Stem Cells (CSCs), are able to sustain self-renewal ability in vitro and have tumorigentic capabilities. CSCs could be visualized as "corrupted" versions of normal stem cells. Because of their ability to self-renew during a lifetime of an individual, these cells could be primary targets of transformation, by acquisition of genetic defects (for example, mutations in tumor suppressor genes and oncogenes) but also by acquiring transcriptional and epigenetic aberrations (3) (4) . Like their normal stem cell counterparts (5) , CSCs are believed to naturally overexpress proteins in the surface that extrude DNA-damaging agents (like the ones used in chemo-therapy for breast cancer) possibly as natural mechanism of stem cells to protect the integrity of their long-life genomes (6-7). Because of their ability to initiate a tumor, their potential to migrate, disseminate and differentiate, and their intrinsic resistance to chemotherapeutic agents, CSCs are primordial targets in breast cancer therapeutics. Recently, the triple negative breast cancer subgroup or basal-like breast cancer, associated with the poorest prognosis in breast cancer patients, has been found enriched in CSCs (8,9) Thus, we are in a critical need for the development of novel technologies to detect and specifically target CSCs, in order to suppress the intrinsic growth capabilities of the tumor.
Our objective is to develop novel technologies to target genes differentially expressed in CSCs, which play a role in maintaining self-renewal and tumorigenicity. We have recently found that the primordial embryonic transcription factor genes, such as SOX2, responsible for self-renewal of embryonic stem cells (10) , are up-regulated in basal-like breast cancer patients, and that their overexpression is associated with poor prognosis (11) . The structure of the chromatin in these selfrenewal gene promoters is a major determinant associated with transcriptional dysregulation and oncogenesis. Chromatin structure and function is controlled in large part by the post-translational modification of histones and the incorporation of specialized histone variants into nucleosomes (12) . Strikingly, histone proteins are highly modified by an array of diverse post-translational modifications, including acetylation and methylation (12) . The large number of modifications and the ability of individual histones to be multiply modified has given rise to the idea that a "histone code" may exist that acts in a combinatorial manner to elicit distinct biological effects (13) (14) . This code is thought to function through the physical alteration of chromatin structure and/or through the recruitment of effector proteins to the sites of histone modification (12) . Several histone modifications have been linked to oncogenesis and cancer stem cell biology (15) (16) (17) (18) . Histone H3 lysine 9 (H3K9) methylation, for example, is critical for gene repression and heterochromatin formation through the recruitment of heterochromatin protein 1, which binds the methyllysine residue (19) (20) (21) . In contrast, the methylation of H3 lysine 4 (H3K4) is linked to transcriptional activation via the recruitment of TFIID and several chromatin-remodeling and modifying enzymes (22) (23) (24) . Histone methylation was once considered to be irreversible, however, recent identification of lysine-specific histone demethylases (KDMs) has revealed histone methylation to be a dynamically regulated process (25) (26) . KDMs contain a JmjC domain, a signature motif conserved from yeast to humans (27) . To date, there have been a number of H3K4 demethylases identified, including PLU-1 (JARID1B) (25) (26) . H3K4 demethylation can help maintaining a repressed chromatin state (28) . The diversity of chromatin "editing" enzymes underscores the importance of the epigenetic landscape in controlling gene expression. Further, our ability to stabily alter gene expression states via epigenetic reprograming is likely to have far reaching implications for controling human deseases including breast cancer (15, 29) . This Idea Award proposal aims to specifcally test the utility of targeting the enzymes that methylate or demethylate these lysine residues in order to shut down the expression of genes that promote breast cancer stem cell renewal. We propose the construction of novel factors named Designed Epigenetic Remodeling Factors (DERFs). DERFs will be targeted to specific selfrenewal promoters using engineered arrays of six-Zinc Finger (ZF) domains, which target 18-bp sites and potentially have unique specificity in the human genome. The result of this work should lead to the generation of novel chromatin remodeling factors targeting CSC self-renewal and tumorigenicity.
BODY
In this section we will describe the main results and conclusions for the tasks outlined in the statement of work for year 1 (months 1-12) of this proposal. 
List of Tasks and expected outcomes:

. To perform DNA-Binding analyses (ELISA).
To verify that the proteins bind DNA well, we will perform routine DNA-binding analyses in vitro (for example, to calculate the dissociation constant, Kd, of these proteins for their cognate substrates by ELISA). These protocols and methods are well established in the Blancafort lab and using previously published conditions. These analyses will be run every month for each 6ZF DNA-binding protein constructed.
Final product after month number 6 (Blancafort):
At the end of the first 6 months the Blancafort laboratory will have completed the construction, cloning and in vitro characterization of five different 6ZF DNA-binding domains.
b) To generate fusions of the engineered 6ZFs with specific panel of Histone modifying domains (Strahl). (months 1-6).
In these experiments, DNA binding domains (made of ZF domains) will be linked to a specific set of modular histone modifiers. The construction of these fusions should be completed by the end of month 6. Final product after month number 6 (Strahl): At the end of the first 6 months the Strahl laboratory will have completed the construction and cloning (in the retroviral expressing vector) of the chromatinmodifying domains. These constructs will be all verified by DNA sequencing. (Blancafort) and to trigger specific epigenetic silencing by ChIP assay (Strahl) . Months 6-9
c) To assess the capability of these fusions to regulate endogenous SOX2 expression by realtime/western analysis
Obtained Results and Discussion:
Previous work and follow-up work from year 1.
We have constructed four 6ZF proteins recognizing highly specific sequences in the Sox2 human promoter: three close to the ATG start site, and one additional ZF protein binding the SRR1 enhancer, which controls Sox2 expression and is critically modified by DNA methylation [30] . The 6ZF domains were first linked to the Kruppel Associated Box (SKD) repressor domain, which has been shown to promote HDAC-dependent repression when linked to ZFs [31, 32, 33] . These constructs were expressed using retroviral vectors in breast cell lines carrying high Sox2 expression [34] . Repression of Sox2 was measured by qRT-PCR and western blot, and normalized to mock-transduced cells. As shown in Fig 1A, all constructs except ZF-619 were properly expressed in MDA-MB-435s cells. ZFs -552 and -598 knock-down Sox2 mRNA and protein expression levels, even with higher potency than siRNAs (Fig 1B-C) . Further, when the proximal 6ZF domains were linked to DNA methyltransferase 3a (DNMT3a), but not with a catalytic mutant, a repression of Sox2 was observed (Fig 2) . Silencing of Sox2 led to a strong suppression of cell proliferation and anchorage independent growth inhibition of MDA-MB-435s cells (Fig 3) . To verify that the DNMT3a constructs are catalytically active we measured DNA me frequencies using the Sequenom EpiTyper platform (Yale).
We have begun preliminary data with previously characterized 6ZF domains targeting the maspin promoter (ZF-97; [35] ) in the SUM159 breast cell line. As shown in Fig.4 , when transduced in SUM159 cells, the ZF97DNMT3a but not SKD or controls, induced DNA me in the CpG islands adjacent to the 6ZF-binding site. MDA-MB-231 cells were processed as positive control for DNA me [36] . Interestingly, recent data shows that individual ZF-97Dnmt3a transduced clones (but not catalytic death mutants or untargeted Dnmt3a) retained DNA me frequencies for more than 50 days post-transduction, even though the retroviral constructs were not longer expressed. In conclusion, our data suggest that our Dnmt3a constructs induced directional, targeted methylation transmitted over cell generations and thus, 6ZFDnmt3a constructs were able to stably reprogram the promoter.
KEY RESEARCH ACCOMPLISHMENTS
-Constructed four 6ZF proteins recognizing highly specific sequences in the Sox2 human promoter.
-Two 6ZF proteins knock-down Sox2 mRNA and protein expression levels, even with higher potency than siRNAs.
-When the proximal 6ZF domains were linked to DNA methyltransferase 3a (DNMT3a), but not with a catalytic mutant, a repression of Sox2 was observed.
-Silencing of Sox2 led to a strong suppression of cell proliferation and anchorage independent growth inhibition of MDA-MB-435s cells.
-When transduced in SUM159 cells, the ZF-97DNMT3a but not SKD or controls, induced DNA me in the CpG islands adjacent to the 6ZF-binding site.
REPORTABLE OUTCOMES ABSTRACTS AND MANUSCRIPTS:
Stolzenburg, S., Yuan, X., Rots, M.G., Strahl, B.D., Blancafort 
CONCLUSION
We have generated arrays of Artifical Transcription Factors (ATFs) made of specific six-zinc finger domains (ZF) targeting unique 18-base pair sites in the SOX2 promoter. The 6ZFs were linked to the repressor domain Krüppel Associated Box (KRAB) domain or DNA methyltransferase 3a (DNMT3a) catalytic domain and expressed in aggressive MDA-MB-435s breast cancer cells using retroviral vectors. Our results show that two ATFs were able to silence SOX2 mRNA and protein levels with virtually 100% down-regulation. This was accompanied with a potent suppression of both tumor cell proliferation and anchorage independent growth. These epigenetic switches represent a promising therapeutic strategy to effectively target breast cancer stem cells.
